Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II proof concept study of RLM023 for Acne-vulgaris.

Trial Profile

Phase II proof concept study of RLM023 for Acne-vulgaris.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hypochlorous acid (Primary)
  • Indications Acne vulgaris
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 17 Jul 2018 According to a Realm Therapeutics media release, the company has discontinued all programs which were based on Company's proprietary technology including RLM-023, after the PR-022 Atopic Dermatitis study results did not meet the company's threshold for continued investment.
    • 15 Mar 2018 New trial record
    • 12 Mar 2018 According to a Realm Therapeutics media release, company intends to file an Investigational New Drug (IND) application in early Q4 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top